Introduction
============

Lung cancer is the leading cause of cancer-related deaths worldwide[@B1], with an estimated 18 million new cases and 16 million deaths worldwide each year[@B2]. Lung cancer is divided into two primary types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC accounts for approximately 15% of all lung cancers, while NSCLC accounts for approximately 85% of all lung cancers[@B3]. Most lung cancer patients are in the middle and late stages of diagnosis, with a 5-year survival rate of \<15%, moreover, the 2-year survival rate of patients with SCLC is as low as 9%, whereas the mortality rate during the last five years after diagnosis in patients with SCLC is as high as 90%. Therefore, the prognosis of patients with advanced lung cancer is very poor[@B4], [@B5]. The main treatment methods for lung cancer include surgery, chemotherapy, radiotherapy and immunotherapy. Platinum-based chemotherapy is most commonly used in patients with advanced or recurrent NSCLC and ED-SCLC (Extensive Disease Small Cell Lung Cancer)[@B3], [@B6], [@B7]. However, the long-term benefit of first-line chemotherapy is limited, and some studies showed that median overall survival was only 8 months in patients with advanced NSCLC patients, and only 9 months in the patients with ED-SCLC[@B8], [@B9]. In recent years, biological agents, such as bevacizumab and cetuximab, among others, have been added to chemotherapy regimens. These regimens have been compared with chemotherapy alone, and these combinations have not revealed an obvious difference in survival, and thus we urgently need novel effective treatments[@B10]-[@B13].

Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a type of leukocyte differentiation antigen, is a transmembrane receptor on T cells and shares B7 molecular ligands with CD28. The binding of CD28 following antigen receptor engagement provides a costimulatory signal required for T cell activation. However, upon binding B7 molecules, CTLA-4 induces T cell reactivity, and it participates in the negative regulation of the immune response, which is a negative regulator of T lymphocytes[@B14], [@B15]. Ipilimumab is a completely anthropogenic IgG1 type of monoclonal antibody that can specifically hinder the binding of CTLA-4 to its ligand (CD80 / CD86) and that can enhance the T cell response *in vivo* and *in vitro*. Ipilimumab can then stimulate tumor- specific T cell proliferation, which leads to the infiltration of T cells into the tumor, and ultimately, tumor regression[@B16]-[@B19]. Early clinical trials of ipilimumab demonstrated its anti-tumor activity against multiple solid tumors[@B20], [@B21]. In a preclinical study model, cisplatin can increase the expression of FAS-cell death receptors on tumor cells, thereby enhancing CTL -mediated anti-tumor immunity[@B22]. In a preclinical tumor model, certain chemotherapy regimens can increase the anti-tumor activity of anti-CTLA-4 antibodies. In a pre-clinical mouse tumor model, ipilimumab blockade of CTLA-4 has been shown to enhance the efficacy of chemotherapy[@B23], [@B24]. This demonstrates that the combination of ipilimumab and chemotherapy is synergistic.

To further clarify the efficacy and safety of chemotherapy combined with ipilimumab immunotherapy for lung cancer patients, we conducted a meta-analysis on previous clinical studies, and more specifically, on relevant Randomized Controlled Trials (RCTs). We hope that this study will provide evidence-based medicine for clinical application.

Materials and methods
=====================

Search strategy
---------------

This meta-analysis is based on the PRISMA guidelines (Supplementary Table [S1](#SM0){ref-type="supplementary-material"}). We searched for studies in PubMed, Web of Science, EMBASE, the Cochrane Library and cliniclatrials.gov and did not have limits regarding the date; the final retrieval occurred on 2018/01/24. The searching keywords were Lung Neoplasms, Ipilimumab, and randomized controlled trial. The specific papers retrieved from each database are provided in the [Supplementary material](#SM0){ref-type="supplementary-material"} (Supplementary Table [S2](#SM0){ref-type="supplementary-material"}).

Eligibility/Exclusion criteria
------------------------------

### Inclusion criteria

Population studied: adults (\> 18 years of age) with a diagnosis of lung cancer with the pathological type, including NSCLC and SCLC;Types of studies: randomized controlled trials;Intervention measures: the control group received chemotherapy alone, and the experimental group received the same chemotherapy regimen combined with ipilimumab immunotherapy;Endpoints: overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), immune-related (ir)-PFS/ORR/DCR, and events that show efficacy and safety.Studies published in English.

### Exclusion criteria

It has been reported that literature that focuses on other unrelated tumor types or on early NSCLC and LD-SCLC (limited-disease small cell lung cancer) will not be included;Review articles, meta-analyses, case reports, editorials, single-arm trials, and studies on other types of non-RCTs will not be included.

Study Selection and Data Extraction
-----------------------------------

Two reviewers (Hm Zhang, J Shen) independently evaluated the title and abstract of each document according to the inclusion criteria and then conducted a full-text retrieval evaluation of the documents that conformed to the inclusion criteria. The selection of the research and the data extraction were independently performed by two investigators, who finally reached a consensus. Any disagreements were discussed and resolved by a third investigator (P Luo).

The primary end points of this assessment were the 6-month/1-year OS, the 6-month/1- year PFS and the 6-month/1-year irPFS of lung cancer patients. Other end points were the ORR, DCR, irORR, irDCR, and safety. Moreover, the meta-analysis also includes data on complete response/immune-related complete response (CR/irCR), partial response/immune-related partial response (PR/irPR), progressive disease/immune-related progressive disease (PD/ irPD), stable disease/immune-related stable disease (SD/irSD). Furthermore, the data on toxic adverse events of the hematologic system, dermatological system, gastrointestinal system, neuromuscular system and other areas of the body was also summarized.

The following data were extracted: the first author\'s last name, country and territory, study type, published year, the study period, the number of subjects in the test group and control group and the percentage of females in each group, histological type, tumor stage, intervention and treatment time, and the efficacy and safety results.

Quality Assessment
------------------

Two investigators (HM Zhang, J Shen) used the Cochrane Collaboration\'s risk of bias tool to assess the quality of the methods used in the included RCTs. The assessment included the following: sequence generation, allocation concealment, blinding, incomplete outcome data addressed, free of selective outcome reporting, and other possible sources of bias[@B25]. Each project is classified as low risk, high risk, and unknown risk for the RCT evaluation. In the same way, the two investigators independently conducted the literature quality assessment and finally reached an agreement. Any disagreements were discussed and resolved by a third investigator (P Luo).

Statistical analysis
--------------------

We used Review Manager 5.3 software (Cochrane Library, Oxford, UK) to perform a statistical analysis of the data, and the corresponding subgroup analyses for the end points of SCLC and NSCLC were also conducted[@B26]. The results of this study are presented by the risk ratio (RR) of the endpoints and the 95% confidence interval (CI) of the various effect size. All p values are bilateral, and p values less than 0.05 indicate a significant difference. In addition, the I^2^ statistic test was used to evaluate the heterogeneity of the data in the study group, and an I^2^ less than 50% indicated no obvious heterogeneity[@B27]. When no obvious heterogeneity was found among the studies, the fixed effect model was used, but otherwise, the random effect model was used. In addition, a sensitivity analysis was conducted to assess the stability of the results. We estimated the publication bias by evaluating the symmetry of the funnel plot; in addition, the potential publication bias was measured by Begg\'s and Egger\'s test using STATA software[@B28], [@B29].

Ethics committee approval is not applicable in this meta-analysis.

Results
=======

Study selection
---------------

319 potential relevant studies were retrieved from 5 databases, and 248 remained after the duplicate literatures were removed. In all, 241 studies were excluded after the title and abstract were read; these excluded studies consisted of irrelevant studies, reviews, case studies, meta-analyses, and studies not published in English. Then, according to the inclusion criteria described above, the authors further evaluated the suitability of the other seven articles. Next, we excluded non-randomized controlled clinical studies and single-arm studies. Finally, four studies[@B30]-[@B33] were included in the final meta-analysis. When a study featured multiple experimental groups but only one control group, we divided the control group into two groups so that each corresponded with the two experimental groups, and for dichotomous outcomes, both the number of events and the total number of patients were divided[@B34]. The studies by Lynch (2012)[@B30] and Reck (2013)[@B31] were thus divided each control group into two groups. Finally, this meta-analysis included 6 clinical randomized controlled studies, and the PRISMA flowchart of the study is shown in Figure [1](#F1){ref-type="fig"}.

Study Characteristics and quality appraisal
-------------------------------------------

The six studies included 2,037 patients with lung cancer, including 953 patients with advanced or recurrent NSCLC and 1084 cases of ED-SCLC. Among them, 1089 received immunochemotherapy, and 948 patients received chemotherapy alone. The baselines values were comparable because all studies focused primarily on platinum-based chemotherapy. The characteristics of each study are in Table [1](#T1){ref-type="table"}[@B35]. The bias risk assessment of each study is summarized in Supplementary Figure [S1](#SM0){ref-type="supplementary-material"}.

Effect measures of ipilimumab vs. placebo for various lung cancers
------------------------------------------------------------------

This meta-analysis did not demonstrate that immunochemotherapy increased the 6-month OS compared with chemotherapy alone (79.6% VS. 83.2%, RR=0.97, 95%CI 0.93-1.01, P=0.11), and this result did not indicate much heterogeneity (I^2^=21%, P=0.28). Even more, subgroup analysis suggested that the OS of NSCLC patients in the immunochemotherapy group was inferior to the chemotherapy alone group, and had statistical significance (77.0% VS. 84.8%, RR=0.92, 95%CI 0.87-0.98, P=0.009 ). The 6-month PFS of the immunochemotherapy group was significantly better than that of the chemotherapy alone group, and no heterogeneity was found among the studies (35.0% VS. 30.1%, RR=1.16, 95%CI 1.02-1.31, P=0.02), (I^2^=0%, P=0.71). The analysis showed that immunochemotherapy leads to a significant improvement in the 6-month-irPFS compared with chemotherapy alone (47.5% VS. 29.7%, RR=1.60, 95%CI 1.16-2.20, P=0.004), with no heterogeneity among the studies (I^2^=0%, P=0.86). Additionally, the subgroup analysis indicated that NSCLC and SCLC both showed significant differences between groups (NSCLC: 46.4% VS. 30.3%, RR=1.53, 95%CI 1.02-2.30, P=0.04; SCLC: 49.4% VS. 28.9%, RR=1.71, 95%CI 1.03-2.84, P=0.04). The 1-year OS rates of the intervention group and the control group were 46.2% and 44.3%, respectively. Compared with the control groups, immunochemotherapy did not show survival benefits in the combined 1-year OS analysis (RR=1.05, 95%CI 0.95-1.15, P=0.36), and the results indicated little heterogeneity (I^2^=0%, P=0.58). The 1-year PFS of the immunochemotherapy group and the chemotherapy only group was 10.8% and 7.9%, respectively. The 1-year PFS of the immunochemotherapy group was significantly better than that of the chemotherapy group, with no heterogeneity found among the studies (RR=1.39, 95%CI 1.06-1.84, P=0.02), (I^2^=0%, P=0.89). Moreover, a subgroup analysis indicated that NSCLC also showed significant differences between groups (13.9% VS. 10.1%, RR=1.50, 95%CI 1.05-2.13, P=0.02). The forest plot did not reveal a benefit of immunochemotherapy versus chemotherapy alone in terms of the 1-year irPFS (11.7% VS. 9.0%, RR=1.33, 95%CI 0.57-3.10, P=0.50), and the results did not indicate much heterogeneity (I^2^=22%, P=0.28) (Figure [2](#F2){ref-type="fig"}).

The ORR/irORR rates for immunochemotherapy and chemotherapy alone were 50.0%/39.5% and 52.3%/32.4%, respectively. No significant differences were found in the ORR (RR=1.00, 95%CI 0.87-1.13, P=0.95) or in the irORR (RR=1.24, 95%CI 0.93-1.67, P=0.15) between groups. The results for the ORR also did not show much heterogeneity among the studies (I^2^=25%, P=0.25), while the results for the irORR revealed little heterogeneity (I^2^=0%, P=0.55). The rate of DCR/irDCR for immunochemotherapy and chemotherapy alone were 82.0%/81.6% and 87.7%/87.4%, respectively. Significant differences were observed in the DCR between groups (RR=0.92, 95%CI 0.85-1.00, P=0.04), but the results of the DCR showed a large amount of heterogeneity among the studies (I^2^=62%, P=0.02). However, no significant differences were observed in the irDCR between the two groups (RR=0.94, 95%CI 0.85-1.03, P=0.20), with a small amount of heterogeneity (I^2^=24%, P=0.26) (Figure [3](#F3){ref-type="fig"}). In addition, the results of the analysis of the CR/irCR, PR/irPR, PD/irPD and SD/irSD are shown in Supplementary Table [S3](#SM0){ref-type="supplementary-material"}.

The overall incidence of grade Ⅲ/Ⅳ AEs was 52.7% for the immunochemotherapy group and 41.3% for the chemotherapy group. No significant differences were found between the groups (RR=1.27, 95%CI 0.99-1.65, P=0.06). Grade Ⅲ/Ⅳ trAEs were observed in 48.7% and 40.2% of patients who received immunochemotherapy and chemotherapy alone, respectively. The differences were statistically significant, and a higher heterogeneity was found among the studies (RR=1.25, 95%CI 1.03-1.51, P=0.02), (I^2^=51%, P=0.07); moreover, a subgroup analysis indicated that, for NSCLC, significant differences were observed between the groups (49.4% VS. 35.9%, RR=1.37, 95%CI 1.13-1.66, P=0.002). The incidence of grade Ⅲ/Ⅳ irAEs was 18.0% and 7.3% of patients who received immunochemotherapy and chemotherapy alone, respectively (RR=2.47, 95%CI 1.19-5.09, P=0.01), and no heterogeneity was found among the studies (I^2^=0%, P=0.96). The rate of grade Ⅲ/Ⅳ AE-related discontinuations was 16.5% and 3.0% for the immunochemotherapy group and the chemotherapy group, respectively. The differences were also statistically significant (RR=2.76, 95%CI 1.15-6.61, P=0.02), and a large amount of heterogeneity was found in the studies (I^2^=70%, P=0.005). The subgroup analysis indicated that, for NSCLC, significant differences were observed between groups (16.9% VS. 3.3%, RR=3.63, 95%CI 1.30-10.13, P=0.01). The incidence of grade Ⅲ/Ⅳ serious AEs was 24.7% for the immunochemotherapy group and 10.0% for the chemotherapy group, respectively. The differences were statistically significant (RR=2.50, 95%CI 1.60-3.90, P\<0.0001) (Figure [4](#F4){ref-type="fig"}). In addition, the result of the analysis of the hematologic system, dermatological system, gastrointestinal system, neuromuscular system and toxic adverse events that occurred in other areas are shown in Table [2](#T2){ref-type="table"}.

Publication bias
----------------

We used the funnel plots to determine the publication bias of the 6-month/1-year OS, the 6-month/1-year PFS, the ORR, DCR, trAEs and AE-related discontinuation (Supplementary Figure [S2](#SM0){ref-type="supplementary-material"}). The shape of the individual funnel plots showed a slight asymmetry, and the power of the test was insufficient because of a small number of studies. We also used STATA 14 software for Begg\'s and Egger\'s test for the 8 effect sizes mentioned above. The results demonstrated that only the 6-month-PFS and AE-related discontinuation may have shown potential bias (P\<0.1). No obvious bias was indicated for the other endpoints[@B28], [@B29].

Discussion
==========

Platinum-based chemotherapy has always been the standard treatment for the majority of advanced patients with lung cancer including NSCLC and ED-SCLC, but its clinical efficacy is limited, as a result, new treatments are emerging, including the addition of monoclonal immunotherapy[@B8], [@B11], [@B36]. Ipilimumab is a monoclonal antibody that binds the CD28 homolog CTLA-4, and upon binding, enhances the costimulation of T cells at their receptor by allowing the binding of CD28 to members of the B7 family on antigen-presenting cells[@B16]. In recent years, many studies have mentioned that immunotherapy and ipilimumab can enhance the therapeutic effect in cases of NSCLC and SCLC[@B37]-[@B39].

This meta-analysis suggests that chemotherapy combined with ipilimumab immunotherapy may improve the 6-month PFS/irPFS and the 1-year PFS compared with chemotherapy alone in patients with advanced or recurrent NSCLC and ED-SCLC. This improvement should be closely connected with the effect of ipilimumab\'s, and many studies have reported similar results[@B40], [@B41]. Arriola E et al. suggested that the median PFS was 6.9 months (95% CI: 5.5 7.9), that the median irPFS was 7.3 months (95% CI: 5.5 8.8) and that the median OS was 17.0 months (95% CI: 7.9 24.3) in patients with ED-SCLC after they were treated with ipilimumab immunotherapy. They also showed that chemotherapy plus ipilimumab immunotherapy was beneficial for some patients with advanced SCLC[@B42]. However, in this meta-analysis, it was not suggested that chemotherapy combined with ipilimumab immunotherapy could improve the 6-month/1-year OS of patients with advanced or recurrent NSCLC and ED-SCLC. Previous studies have shown that the survival of NSCLC patients can improve when tumor infiltration by immune cells (CD4+/CD8+Tcells) is enhanced [@B43]-[@B46]. The results of this meta-analysis are somewhat inconsistent with this statement. One reason for this discrepancy is that the included patients all had advanced lung cancer, that those patients were prone to distant metastasis and recurrence, or that they had a poor prognosis[@B4]. Another reason is that ipilimumab enhanced the infiltration of the tumor cells via blocking CTLA-4 and a series of signal transduction pathways, but this did not completely eliminate the tumor cells.

This study further demonstrated that the ORR/irORR, and DCR/irDCR did not improve significantly as a result of the chemotherapy combined with ipilimumab immunotherapy. In addition, the integrated patients with lung cancer in the chemotherapy combined with ipilimumab immunotherapy group had a slightly inferior DCR than the chemotherapy group (82.0% vs. 87.7% RR=0.92, 95%CI 0.85-1.00, P=0.04). In 2016, a phase I/II CheckMate 032 study (nivolumab VS. nivolumab+ipilimumab) that included 216 patients with SCLC found that the RSS was 19% and 23%, respectively, and that the DCRs were 36% and 42%, respectively. They also found that, for the nivolumab and the nivolumab plus ipilimumab groups, the ORRs were 13% and 31%, respectively, and that the median OS was 3.6 months and 7.8 months, respectively[@B47]. However, our ED-SCLC cases did not show a statistical advantage in terms of the efficacy of chemotherapy combined with ipilimumab immunotherapy in the subgroup analysis. A benefit is not ruled out because of the differences between nivolumab and chemotherapeutic drugs because the patients themselves might have had an advanced stage of the disease, and because these rates are associated with the natural progression of the disease and the extent of tumor shrinkage.

We also performed a detailed subgroup analysis of the SCLC and NSCLC patients, which was similar to the comprehensive statistical results of all lung cancer patients, but there were still some important findings. For patients with advanced or recurrent NSCLC, the 1-year PFS of patients in the chemotherapy combined with ipilimumab treatment group was improved (13.9% VS. 10.1% RR=1.50, 95%CI 1.05-2.13, P=0.02), but for patients with ED-SCLC, no statistically significant difference was found between the two groups, whether the chemotherapy of each group is paclitaxel combined with carboplatin (TC) or etoposide combined with carboplatin/cisplatin (EC) (Supplementary Figure [S3](#SM0){ref-type="supplementary-material"}). This may have depended on the exact tumor type of SCLC and NSCLC. Surprisingly, 6months-OS of patients with NSCLC was lower in chemotherapy plus ipilimumab group than in chemotherapy alone group(77.0% VS. 84.8% RR=0.92, 95%CI 0.87-0.98, P=0.009), while for patients with ED-SCLC, whether the chemotherapy is TC or EC, no statistically significant difference was observed between the two groups (Supplementary Figure [S3](#SM0){ref-type="supplementary-material"}). Although TC was rarely used for the treatment of ED-SCLC, the difference between this chemotherapy and the standard chemotherapy method EC did not affect the primary results of this meta-analysis. And of course, this finding suggests that ipilimumab does not improve the overall survival. This may be related to the points discussed above in that the patients included in the study have advanced disease and are prone to distant metastasis and recurrence. Moreover, ipilimumab may stimulate T cells that have infiltrated the tumor and may not completely eradicate the tumor cells. This meta-analysis also has a limited sample size. And we should take an objective view of its analysis results.

In addition, subgroup analysis was also performed for the split phased-ipilimumab regimen and concurrent-ipilimumab regimen. For primary outcome, the results are similar to the overall results, but there were still some differences. The 6months-OS of patients with NSCLC in phased-ipilimumab regimen was lower in chemotherapy plus ipilimumab group than in chemotherapy alone group (78.3% VS. 85.8% RR=0.92 95%CI 0.86-0.98, P=0.009), this is consistent with the above results, while in concurrent-ipilimumab regimen, no statistically significant difference was observed between the study group and control group. Perhaps such results suggest that phased-ipilimumab regimen makes ipilimumab less meaningful than concurrent-ipilimumab regimen. And of course, this suggests that ipilimumab does not improve the overall survival. We hypothesized that this effect might be altered by an increase in the sample size of the concurrent-ipilimumab group (Supplementary Figure [S4](#SM0){ref-type="supplementary-material"}).

Quality of life is particularly important for cancer patients. Chemotherapy is a first-line treatment for cancer, and thus its toxic adverse events are the focus of patients and medical professionals. For cisplatin, a drug that highly induces vomiting is the gold standard for adjuvant chemotherapy. Since carboplatin causes less vomiting than cisplatin, it is more internationally recommended for patients with more complications, although it is still not possible to avoid the toxic effects of chemotherapy drugs[@B48]. Ipilimumab can specifically block the binding of CTLA-4 and its ligand (CD80/CD86) to achieve an immunotherapeutic effect[@B18]. However, the immune function of the human body has different degrees of influence. Immune checkpoint blockers (ICBs) strengthen the immune response against tumor cells, but they also cause immune-related adverse events[@B49]. We compared the grade III/IV toxicities in the two groups and found that the chemotherapy combined with ipilimumab immunotherapy group had the highest incidence of tr-AEs, ir-AEs, serious AEs and AE-related discontinuation and determined that the difference was statistically significant. Ipilimumab did not aggravate fatigue, alopecia, vomiting, nausea and other chemotherapy-related adverse events, but immune-related skin mucosal toxicity was aggravated by the addition of ipilimumab.

In addition, there are two potential limitations of this meta-analysis:although we performed a detailed subgroup analysis for advanced or recurrent NSCLC and SCLC patients, a comprehensive analysis revealed that these patients will inevitably have more sources of heterogeneity because of different tumor types;for the studies by Lynch et al.[@B30] and Reck et al[@B31], we divided the control group into two separate groups so that they corresponded to the two experimental groups, which also increased the sources of heterogeneity[@B34].

Conclusions
===========

In summary, chemotherapy combined with ipilimumab immunotherapy cannot improve the OS, ORR, DCR of patients with lung cancer (NSCLC, ED-SCLC) compared with chemotherapy alone, but it can improve the patient\'s 6-month/1-year PFS and 6-month-irPFS; a subgroup analysis suggests that 1-year PFS is more improved in patients with advanced or recurrent NSCLC in the chemotherapy plus ipilimumab immunotherapy group. However, due to the addition of ipilimumab, the tr-AEs, ir-AEs, serious AEs and AE-related discontinuation are relatively higher in this group than in the chemotherapy only group, in which the immune-related toxicities are more apparent, and the quality of the patient\'s life has been affected. We hope this meta-analysis can play a role in evidence-based medicine and clinical work, but we must have a dialectical view of the results. Nevertheless, for further research and exploration, we need additional larger, multi-center studies that include more detailed types of tumors and that strictly control the type and dosage of chemotherapeutics.
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###### 

Baseline characteristics

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                    Country\               Study\        Published year   No. of patients\   Histology type   Clinical stages   Ipilimumab      Placebo                                                      
                             Or Territory           period                         (Female %)                                                                                                                         
  -------------------------- ---------------------- ------------- ---------------- ------------------ ---------------- ----------------- --------------- ------------------------------------------------------------ --------------------------------------------------------------------------------------
  Lynch,T.,\                 US, Europe and India   2008 - 2010   2012             70 (24)            33 (13)          NSCLC^a^          IIIB^c^/IV^d^   I^f^(10mg/kg)+Pac^g^(175mg/m^2^)+Carb^h^(AUC=6);q3w;≤18w┼\   Placebo+Pac^g^(175mg/m^2^)\
  Et al.(a) [@B30]                                                                                                                                       followed by I^f^(10mg/kg);q12w; to PD                        +Carb^h^(AUC=6);q3w;≤18w\
                                                                                                                                                                                                                      followed by\
                                                                                                                                                                                                                      Placebo;q12w; to PD

  Lynch,T.,\                 US, Europe and India   2008 - 2010   2012             68 (28)            33 (13)          NSCLC^a^          IIIB^c^/IV^d^   I^f^(10mg/kg)+Pac^g^(175mg/m^2^)+Carb^h^(AUC=6);q3w;≤18w║\   Placebo+Pac^g^(175mg/m^2^)\
  et al.(b) [@B30]                                                                                                                                       followed by I^f^(10mg/kg);q12w; to PD                        +Carb^h^(AUC=6);q3w;≤18w\
                                                                                                                                                                                                                      followed by\
                                                                                                                                                                                                                      Placebo;q12w; to PD

  Reck, M.,\                 US, Europe and India   2008 - 2011   2013             43 (NR^\*^)        23 (NR^\*^)      SCLC^b^           ED-SCLC^e^      I^f^(10mg/kg)+Pac^g^(175mg/m^2^)+Carb^h^(AUC=6);q3w;≤18w║\   Placebo+Pac^g^(175mg/m^2^)\
  et al.(a)[@B31]                                                                                                                                        followed by I^f^(10mg/kg);q12w; to PD                        +Carb^h^(AUC=6);q3w;≤18w\
                                                                                                                                                                                                                      followed by\
                                                                                                                                                                                                                      Placebo;q12w; to PD

  Reck, M.,\                 US, Europe and India   2008 - 2011   2013             42 (NR^\*^)        22 (NR^\*^)      SCLC^b^           ED-SCLC^e^      I^f^(10mg/kg)+Pac^g^(175mg/m^2^)+Carb^h^(AUC=6);q3w;≤18w┼\   Placebo+Pac^g^(175mg/m^2^)\
  et al.(b) [@B31]                                                                                                                                       followed by I^f^(10mg/kg);q12w; to PD                        +Carb^h^(AUC=6);q3w;≤18w\
                                                                                                                                                                                                                      followed by\
                                                                                                                                                                                                                      Placebo;q12w; to PD

  Reck, M.,\                 North America,\        2011 - 2015   2016             478 (34)           476 (32)         SCLC^b^           ED-SCLC^e^      I^f^(10mg/kg),cycle3-6+Eto^i^(100mg/m^2^)+Cisp^j^\           Placebo,cycle3-6+Eto^i^(100mg/m^2^)+Cisp^j^(75mg/m^2^)/Carb^h^(AUC=5),cycle1-4;q3w;\
  et al. [@B32]              South America,\                                                                                                             (75mg/m^2^)/Carb^h^(AUC=5), cycle1-4;q3w\                    followed by\
                             Europe\                                                                                                                     followed by\                                                 Placebo;q12w; to PD
                             and Asia                                                                                                                    I^f^(10mg/kg); q12w; to PD                                   

  Govindan,R.,et al.[@B33]   North America,\        2011 - 2015   2017             388 (16)           361 (14)         NSCLC^a^          IV^d^ or\       I^f^(10mg/kg),cycle3-6+Pac^g^(175mg/m^2^)+Carb^h^\           Placebo,cycle3-6+Pac^g^(175mg/m^2^)+Carb^h^(AUC=6),cycle1-6;q3w;\
                             South America,\                                                                                             recurrent       (AUC=6),cycle1-6;q3w\                                        followed by\
                             Europe\                                                                                                                     followed by I^f^(10mg/kg);q12w; to PD                        I^f^(10mg/kg); q12w; to PD
                             and Asia                                                                                                                                                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^: Non-Small-Cell Lung Cancer; ^b^: Small Cell Lung Cancer; ^c^: Clinical stages IIIB is T~1-4~N~3~M~0~, T~4~N~2-3~M~0~; ^d^: Clinical stages IV is T~1-4~N~0-3~M~1~; ^e^: extensive stage-Small Cell Lung Cancer is the lesion exceeds the restricted range; ^f^: Ipilimumab; ^g^: Paclitaxel; ^h^: Carboplatin; ^i^: Etoposide; ^j^: Cisplatin. TNM stages: The Tumor, Node, Metastasis (TNM) staging system, adopted by both the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC), and the new edition (8th) of the staging manual was published in January 2017[@B35]. ┼: concurrent-ipilimumab regimen (four doses of ipilimumab/paclitaxel (Taxol)/carboplatin followed by two doses of placebo/paclitaxel/carboplatin). ║: phased-ipilimumab regimen (two doses of placebo/paclitaxel/carboplatin followed by four doses of ipilimumab/paclitaxel/carboplatin). ^\*^:NR: not reported.

###### 

Results of the meta-analyses examining the adverse events between pure chemotherapy group and chemotherapy plus ipilimumab group

  --------------------------------------------------------------------------------------------------
  Toxicity                      N   Ipilimumab   Placebo     RR \[95% CI\]          Heterogeneity\
                                                                                    (I^2^, P)
  ----------------------------- --- ------------ ----------- ---------------------- ----------------
  **Hematologic**                                                                   

  Anemia                        6   103 / 1088   86 / 946    1.06 \[0.81-1.40\]     34%,0.18

  •SCLC                         3   45 / 562     55 / 520    0.77 \[0.53-1.12\]     0%, 0.60

  •NSCLC                        3   58 / 526     31 / 426    1.56 \[1.02-2.37\]     0%, 0.82

  Leukopenia                    2   17 / 866     27 / 837    0.61 \[0.33-1.11\]     42%, 0.19

  Neutropenia                   6   138 / 1088   171 / 946   0.75 \[0.61-0.92\]     45%, 0.10

  •SCLC                         3   76 / 562     114 / 520   0.64 \[0.49-0.84\]     25%, 0.26

  •NSCLC                        3   62 / 526     57 / 426    0.94 \[0.67-1.31\]     31%, 0.23

  Thrombocytopenia              6   53 / 1088    42 / 946    0.89 \[0.41-1.90\]     51%, 0.07

  •SCLC                         3   22 / 562     22 / 520    0.91 \[0.51-1.63\]     0%, 0.82

  •NSCLC                        3   31 / 526     20 / 426    0.52 \[0.08-3.21\]     78%, 0.01

  **Gastrointestinal**                                                              

  Diarrhea                      6   77 / 1088    13 / 946    3.95 \[1.97-7.95\]     18%, 0.30

  •SCLC                         3   41 / 562     5 / 520     3.80 \[0.78-18.51\]    55%, 0.11

  •NSCLC                        3   36 / 526     8 / 426     3.52 \[1.65-7.51\]     0%, 0.61

  Nausea                        6   10 / 1088    5 / 946     1.40 \[0.51-3.83\]     0%, 0.56

  •SCLC                         3   7 / 562      4 / 520     0.97 \[0.09-10.58\]    54%, 0.14

  •NSCLC                        3   3 / 526      1 / 426     1.11\[0.20-6.35\]      0%, 0.69

  Vomiting                      4   9 / 1004     7 / 902     1.05 \[0.40-2.70\]     0%, 0.77

  •SCLC                         1   5 / 478      3 / 476     1.66 \[0.40-6.91\]     NA

  •NSCLC                        3   4 / 526      4 / 426     0.69 \[0.18-2.60\]     0%, 0.86

  **Dermatological**                                                                

  Rash                          6   22 / 1088    1 / 946     5.75 \[1.88-17.57\]    0%, 0.42

  •SCLC                         3   10 / 562     0 / 520     8.87\[1.27-62.18\]     0%,0.37

  •NSCLC                        3   12/ 526      1 / 426     4.34\[1.09-17.26\]     22%,0.28

  Pruritus                      6   8 / 1088     1 / 946     2.12 \[0.36-12.59\]    27%, 0.25

  •SCLC                         3   4 / 562      0 / 520     3.51 \[0.40-30.44\]    0%, 0.50

  •NSCLC                        3   4 / 526      1 / 426     1.21 \[0.02-61.85\]    70%, 0.07

  **Neuromuscular**                                                                 

  Peripheral neuropathy         5   4 / 610      2 / 470     1.47 \[0.30-7.30\]     0%, 0.32

  •SCLC                         2   0 / 84       0 / 44      NA                     NA

  •NSCLC                        3   4 / 526      2 / 426     1.47 \[0.30-7.30\]     0%, 0.32

  Peripheralsensoryneuropathy   5   8 / 610      6 / 470     0.98 \[0.37-2.60\]     0%, 0.43

  •SCLC                         2   0 / 84       0 / 44      NA                     NA

  •NSCLC                        3   8 / 526      6 / 426     0.98 \[0.37-2.60\]     0%, 0.43

  **Others**                                                                        

  Fatigue                       6   40 / 1088    16 / 946    1.87 \[1.06-3.31\]     0%, 0.46

  •SCLC                         3   19 / 562     3 / 520     4.54 \[1.44-14.31\]    0%, 0.39

  •NSCLC                        3   21 / 526     13 / 426    1.20 \[0.60-2.39\]     0%, 0.96

  Liver-function enzymes        5   35 / 610     5 / 470     3.71 \[1.60-8.60\]     27%, 0.24

  •SCLC                         2   18 / 84      0 / 44      10.16 \[1.40-73.51\]   0%, 0.65

  •NSCLC                        3   17 / 526     5 / 426     2.35 \[0.92-5.99\]     35%, 0.21
  --------------------------------------------------------------------------------------------------

N = number of included studies; RR = relative risk. SCLC: Small Cell Lung Cancer; NSCLC: Non-Small Cell Lung Cancer. NA: not applicable.

[^1]: \*These authors (Hongman Zhang and Jie Shen) contributed equally to this study and should be considered as co-first authors.

[^2]: Competing Interests: The authors have declared that no competing interest exists.
